PBH Stock Forecast & Price Target

Prestige Consumer Healthcare has demonstrated strong growth potential, reflected in the increased EBITDA estimates for 2026 and 2027 by approximately $15 million due to higher assumed sales growth. The organic volume growth rate for Specialty Foods is expected to accelerate in the second half of 2025, supported by significant new product launches and the company's capacity expansions, signaling robust demand and operational efficiency. Furthermore, the company reported positive same-store sales in the U.S. for September and sustained growth in Canada, contributing to a favorable outlook for revenue growth, projected at 18.5% year-over-year for the third quarter of 2025.

Prestige Consumer Healthcare faces a negative outlook primarily due to lower-than-expected revenue growth, which could result in diminished EBITDA margins as input costs continue to rise. The company's significant reliance on North American markets, which generate approximately 85% of total revenue, makes it vulnerable to a weaker operating environment and decreased performance from major customers. Additionally, ongoing cost inflation and potential integration risks following acquisitions pose further challenges to the firm's financial stability and growth prospects.